Fosmanogepix
- Generic Name
- Fosmanogepix
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H21N4O6P
- CAS Number
- 2091769-17-2
- Unique Ingredient Identifier
- 1XQ871489P
- Background
Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).
- Associated Conditions
- -
- Associated Therapies
- -
Antifungal Begins Phase 3 Trial
Basilea Pharmaceutica initiated the FAST-IC phase 3 study to evaluate fosmanogepix, a novel antifungal therapy inhibiting the Gwt1 enzyme, for treating candidemia and invasive candidiasis. The study compares fosmanogepix to caspofungin, with plans to enroll 450 patients globally. Basilea also plans a second phase 3 study for invasive mold infections.
Basilea initiates clinical phase 3 study with antifungal
Basilea Pharmaceutica Ltd initiated the FAST-IC phase 3 study to evaluate fosmanogepix, a novel antifungal, against standard-of-care treatment in invasive candidiasis. Fosmanogepix, with a novel mechanism of action, is available in intravenous and oral formulations and has shown efficacy against various Candida species, including multi-drug-resistant strains. The study aims to enroll 450 patients and is managed by PSI CRO AG.
Biodefense Headlines – 20 September 2024
Strategies for improving Ebola virus disease post-exposure prophylaxis, origin of SARS-CoV-2 linked to Wuhan market, 'scoop and run' best for nerve agent mass casualty events, T cell memory from seasonal flu may offer pre-existing immunity to H5N1.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath